TickerFacts.

Compare

Lexicon Pharmaceuticals, Inc. vs Gossamer Bio, Inc. vs Ocular Therapeutix, Inc vs Protagonist Therapeutics, Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearLexicon Pharmaceuticals, Inc.
LXRX		Gossamer Bio, Inc.
GOSS		Ocular Therapeutix, Inc
OCUL		Protagonist Therapeutics, Inc
PTGX
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$49.80M$48.47M$51.95M$46.02M
Revenue growth (YoY)+60.2%-57.7%-18.5%-89.4%
Gross marginn/an/a87.3% (computed)n/a
Operating margin-98.2%-352.2%-519.8%-343.6%
Net margin-101.1%-351.5%-511.9%-282.8%
Net income-$50.34M-$170.37M-$265.94M-$130.15M
EPS (Diluted)-$0.14-$0.75-$1.42-$2.05
Operating cash flow-$67.85M-$171.27M-$204.88M$57.67M
Free cash flow-$67.85M-$171.34M-$216.89M$56.08M
Cash & equivalents$34.33M$37.73M$737.06M$128.39M
Total assets$184.99M$172.25M$808.06M$668.19M
Total liabilities$77.45M$295.01M$153.75M$53.48M
Shareholders' equity$107.54M-$122.76M$654.31M$614.71M
Return on year-end equity-46.8%n/a-40.6%-21.2%
Shares outstanding365.85M233.68M215.93M62.58M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearLexicon Pharmaceuticals, Inc.Gossamer Bio, Inc.Ocular Therapeutix, IncProtagonist Therapeutics, Inc
Latest$49.80M
Ended 2025-12-31		$48.47M
Ended 2025-12-31		$51.95M
Ended 2025-12-31		$46.02M
Ended 2025-12-31
1 year earlier$31.08M
Ended 2024-12-31		$114.70M
Ended 2024-12-31		$63.72M
Ended 2024-12-31		$434.43M
Ended 2024-12-31
2 years earlier$1.20M
Ended 2023-12-31		$0
Ended 2023-12-31		$58.44M
Ended 2023-12-31		$60.00M
Ended 2023-12-31
3 years earlier$139.0K
Ended 2022-12-31		$0
Ended 2022-12-31		$51.49M
Ended 2022-12-31		$26.58M
Ended 2022-12-31
4 years earlier$298.0K
Ended 2021-12-31		n/a$43.52M
Ended 2021-12-31		$27.36M
Ended 2021-12-31